SCHEMBL3590434

SCHEMBL3590434

COCCN(C)C1Cc2c([NH])cccc2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.41
KDM4E B2RXH2 2/20 0.33
LMNA P02545 1/20 0.33
CHRM2 P08172 1/20 0.33
CYP3A4 P08684 1/20 0.33
HTR1A P08908 1/20 0.33
ADRA2A P08913 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
HTR2A P28223 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590436 0.87 TRPV1 (0.40) TRPV1KDM4ELMNACHRM2CYP3A4
SCHEMBL3598948 0.86 HTR1A (0.34) TRPV1KDM4ELMNACHRM2CYP3A4
SCHEMBL3592385 0.85 TRPV1 (0.38) TRPV1KDM4ELMNACHRM2CYP3A4
SCHEMBL3594028 0.82 TRPV1 (0.40) TRPV1DDB1CRBN
SCHEMBL3593976 0.80 CREBBP (0.34) KDM4ELMNACHRM2CYP3A4HTR1A
SCHEMBL3595539 0.78 HSP90AA1 (0.36) KDM4ELMNACHRM2CYP3A4HTR1A
SCHEMBL3600214 0.77 TRPV1 (0.47) TRPV1DRD2DRD3CASP3
SCHEMBL3603349 0.77 TRPV1 (0.42) TRPV1CASP3
SCHEMBL3584555 0.72 DDB1 (0.36) KDM4EALDH1A1DDB1CRBNTSHR
SCHEMBL3598950 0.72 ALDH1A1 (0.34) KDM4ELMNACHRM2CYP3A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 TRPV1 2518/4885KDM4E 2284/4885LMNA 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.